Trial intelligence / Profile preview

Early ganciclovir treatment for active CMV infection in mechanically ventilated ICU patients with severe sepsis or septic shock

2011-002603-15Phase 2Active

Sponsor
INCLIVA Biomedical Research Institute
Start
Sep 2011
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2 trial of ganciclovir in cytomegalovirus disease (CMV) (2 arms), sponsored by INCLIVA Biomedical Research Institute. Primary endpoint: Virologic negative conversion in blood and tracheal aspirate at day 14. Started Sep 2011; status: active.

02

Drugs

ganciclovir
03

Conditions

cytomegalovirus disease (CMV)

Beyond the preview

Go deeper on 2011-002603-15.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2011-002603-15.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call